A small study of Sanofi’s lixisenatide has suggested that the GLP-1 agonist could slow down the progression of Parkinson’s disease, pointing to another potential use for the fast-growing drug ...

Data Sources: PubMed was searched (to December 5, 2011) using the terms exenatide, liraglutide, albiglutide, and lixisenatide. The search was limited to studies published in English and conducted ...

Insulin, sulfonylureas, and TZDs are diabetes medications that may cause weight gain. But some, like metformin, may have weight loss potential. Others may be neutral to any weight changes. Weight ...

Objective Many societies recommend using estimated glomerular filtration rate (eGFR) rather than serum creatinine (sCr) to determine metformin eligibility. We examined the potential impact of ...

The EMA’s safety committee has said that, after a review of available data, it has found no evidence that GLP-1 agonist drugs such as Novo Nordisk’s Ozempic and Eli Lilly’s Trulicity can ...

Discover the FDA-approved indications for GLP-1 receptors, including diabetes, weight loss, and cardiovascular disease. Learn brand-name and generic options.

This 14-month, phase 2, double-blind, randomised, placebo-controlled clinical trial found that lixisenatide, a glucagon-like peptide-1 receptor agonist-1 antagonist, can improve motor symptoms. 10 The ...

Correspondence to Professor Jacques J G H M Bergman, Gastroenterology and Hepatology, Amsterdam UMC Location AMC, Amsterdam 1105 AZ, The Netherlands; j.j.bergman{at}amsterdamumc.nl Despite important ...